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Background: PEG-based laxatives are considered today the gold standard for the treatment of constipation in
children. PEG formulations differ in terms of composition of inactive ingredients which may have an impact on
acceptance, compliance and adherence to treatment. We therefore compared the efficacy, tolerability, acceptance
and compliance of a new PEG-only formulation compared to a reference PEG-electrolyte (PEG-EL) formulation in
resolving faecal impaction and in the treatment of chronic constipation.
Methods: Children aged 2–16 years with functional chronic constipation for at least 2 months were randomized to
receive PEG-only 0.7 g/kg/day in 2 divided doses or 6.9 g PEG-EL 1–4 sachets according to age for 4 weeks.
Children with faecal impaction were randomized to receive PEG-only 1.5/g/kg in 2 divided doses until resolution or
for 6 days or PEG-EL with an initial dose of 4 sachets and increasing 2 sachets a day until resolution or for 7 days.
Results: Ninety-six children were randomized into the study. Five patients withdrew consent before starting
treatment. Three children discontinued treatment for refusal due to bad taste of the product (1 PEG-only, 2 PEG-EL);
1 (PEG-EL) for an adverse effect (abdominal pain). Intent-to-treat analysis was carried out in 49 children in the
PEG-only group and 42 in the PEG-EL group.
No significant differences were observed between the two treatment groups at baseline.
Adequate relief of constipation in terms of normalized frequency and painless defecation of soft stools was
achieved in all patients in both groups. The number of stools/week was 9.2 ± 3.2 (mean ± SD) in the PEG-only
group and 7.8 ± 2.4 in the PEG-EL group (p = 0.025); the number of days with stool was 22.4 ± 5.1 in the PEG-only
group and 19.6 ± 7.2 in the PEG-EL group (p = 0.034).
In the PEG-only group faecaloma resolution was observed in 5 children on the second day and in 2 children on the
third day, while in the PEG-EL group it was observed in 2 children on the second day, in 3 children on the third
day and in 1 child on the fifth day.
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Only 2 patients reported mild treatment-related adverse events: 1 child in the PEG-only group had diarrhoea and
vomiting and 1 child in the PEG-EL group had abdominal pain requiring treatment discontinuation. The PEG-only
preparation was better tolerated as shown by the lower frequency of nausea than in the PEG-EL group.
In the PEG-only group, 96% of patients did not demonstrate any difficulties associated with treatment, as
compared with 52% of patients in the PEG-EL group (p < 0.001). Also, the PEG-only formulation taste was better
than that of PEG-EL (p < 0.001). The difference between the percentage of subjects who took > 80% of the
prescribed dose was in favour of the PEG-only group (98% vs. 88%), though it did not reach a conventional
statistical level (p = 0.062).
Conclusion: PEG-only was better tolerated and accepted than PEG-EL in children with chronic constipation. At
the higher PEG doses recommended by the manufactures children in the PEG-only group had higher and more
regular soft stool frequency than PEG-EL.
Trial registration: ClinicalTrials.gov: NCT01592734
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Constipation is a very common childhood complaint.
The condition is chronic in more than one third of
patients and is a common reason for referral to second-
ary care [1,2].
In 90-95% of children, constipation is functional,
which means that there is no objective evidence of a
pathological condition [3].
Some factors leading to constipation such as inad-
equate daily fiber intake, insufficient fluid intake, and
poor physical activity are considered to be modifiable.
The most frequent cause in children is development of a
withholding behaviour after experiencing a painful or
frightening evacuation [4].
Painful defecation, in fact, is considered a common
trigger to faecal retention leading to a cycle of fear
and further retention. Retention of faeces can lead to
prolonged faecal stasis in the colon, with reabsorption
of fluids and increase in the size and consistency of
stools. It is often necessary to use a laxative therapy to
achieve comfortable defecation in constipated children.
Polyethylene glycol solution (PEG, or macrogol according
to the international non-proprietary name) is an osmotic
laxative agent that is absorbed in only trace amounts from
the gastrointestinal tract. Nowadays, it is routinely used to
treat chronic constipation in adults [5,6].
PEG-based laxatives have been shown to be effective
and safe for chronic constipation and for resolving faecal
impaction in children [7-12].
Different PEG-based laxatives with [13-17] or without
[18-20] electrolytes are available on the market. All
PEG-based formulations have been shown in placebo-
controlled and active comparator trials to be safe and
effective in the treatment of chronic constipation in
children. However, there is insufficient information regard-
ing the comparison of other features such as tolerability,
palatability and ease of administration [21] between PEGformulations which may influence adherence and, in turn,
provide better constipation management in children.
A new PEG 4000-only laxative with no excipients or
flavourings in a tasteless, odourless powder that can be
mixed with water or any other common beverage has
been recently introduced in the market.
The aim of this randomized study was to compare the
efficacy, tolerability, acceptance and compliance of a
new PEG-only formulation compared to a reference
PEG-electrolyte formulation in resolving faecal impac-
tion and in the treatment of chronic constipation.
Methods
Study design
This was a randomized, single-blind, parallel group study
of a PEG-only laxative vs. a PEG-electrolyte laxative in
the resolution of faecal impaction and the treatment of
chronic constipation.
The study was reviewed by the hospital ethical com-
mittee and was carried out in accordance to Good
Clinical Practice and Declaration of Helsinki. The
investigators obtained a signed informed consent before
patient enrolment.
Patients
Children were eligible if they were aged between 2 and
16 years and had a diagnosis of functional constipation
according to Rome III criteria or showed faecal impac-
tion at physical examination. Symptoms of functional
constipation should have been present for at least 2
months.
Exclusion criteria included children with organic
causes of defecation disorders, such as Hirschsprung dis-
ease, spina bifida, hypothyroidism, or other metabolic or
renal abnormalities; children receiving medication influ-
encing gastrointestinal motility; children with suspected
gastrointestinal obstruction or stenosis.
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PEG-only laxative (OnligolW powder for oral solution,
400-g bottle with measuring spoon, Promefarm srl, Italy).
Faecal impaction: 1.5 g/kg/day divided in 2 doses until
resolution or for max 6 days (fixed dose).
Constipation: in children <20 kg 0.7 g/kg/day; in chil-
dren >20 kg same daily dose with a maximum limit of
30 g daily. The daily dose was divided in 2 administra-
tions. The duration of treatment was 4 weeks.
PEG-electrolyte (MovicolW Bambini powder for oral
solution, 6.9 g sachets (Norgine, Italy).
Faecal impaction: increasing dose up to resolution or
up to a 7-day treatment plan as follows (day 1: 4 sachets;
day 2: 6 sachets; day 3: 8 sachets; day 4: 10 sachets; day
5: 12 sachets; day 6: 12 sachets; day 7: 12 sachets).
Constipation: 1 sachet in children aged 2–6 years; 2
sachets in children aged 7–11 years; 4 sachets in chil-
dren aged 12–16 years.
Randomization and blinding
To ensure a balanced allocation of treatments among dif-
ferent ages, separate computer generated randomized lists
were used for the 3 age groups (2–5 years, 6–11 years,
12–16 years). Because of obvious differences in the treat-
ment appearance and taste, blinding of the participants
and part of study personnel was not possible. The doctor
who performed the evaluation was not involved in the
allocation of treatment and remained blinded as to the
type of treatment received by patients during the study.
Study program
– Visit 1 (Enrolment, -7/-10 days)
At enrolment, before receiving any intervention,
caregivers of patients provided information on
demographics and medical history, and a physical
examination including rectal digital examination (if
needed) was performed. A bowel diary was delivered
to the patient and he/she had to stop laxative intake.
In case of faecal impaction treatment was initiated.
– Visit 2 (T0)
During the second visit, the doctor performed an
evaluation of bowel diaries and the response to
faecal impaction treatment. The patient started the
constipation treatment.
– Visit 3 (+28 days)
During the last visit, bowel diary evaluation was
performed. The doctor also assessed tolerability,
acceptance and patient compliance.
Evaluation of efficacy
– Primary variable:
Stool frequency over the 4 weeks of treatment.– Secondary variables:
Occurrence and timing of faecal disimpaction, stool
consistency, frequency of pain/difficulty in passing
stools over 4 weeks, frequency of soiling episodes
over 4 weeks, parent and child satisfaction, use of
laxative, tolerability (episodes of nausea and
abdominal pain), acceptability (palatability 5-point
scale and ease of administration), compliance with
preparation (> 80% of the prescribed dosage).
Adverse events
All gastrointestinal and non-gastrointestinal unexpected
adverse events which occurred during the study were
collected.
Statistical analysis
Baseline and end-of-treatment characteristics have been
summarized using the usual descriptive statistics: by
count and percentage for qualitative variables and by
mean and standard deviation for quantitative variables.
As regards the efficacy analysis, treatments were com-
pared for each measure by calculating the difference be-
tween the values or the medium frequencies observed in
the period of treatment.
Treatment comparison was carried out using t-test
and chi-square test for quantitative and qualitative vari-
ables, respectively. All tests were considered two-tailed
with significance level set to 5%; 95% confidence inter-
vals were also measured.
Results
Of the 96 children enrolled, 5 withdrew consent before
starting treatment, leaving a total of 91 (Figure 1).
Four children dropped out; 3 of them (1 PEG-only, 2
PEG-EL) due to the bad taste of the product; 1 (PEG-
EL) for an adverse effect. Therefore 49 children in the
PEG-only group and 42 in the PEG-EL group were
included in the intention-to-treat population.
There were no relevant clinical or demographic differ-
ences between the two treatment groups at baseline
(Table 1).
Efficacy
Adequate relief of constipation in terms of normalized
frequency (≥3 per week) and painless defecation of soft
stools was achieved in all patients in both groups.
The mean ± SD number of stools/week in the PEG-only
and PEG-EL groups, respectively, were 9.2 ± 3.2 vs. 7.8 ±
2.4 stools (p = 0.025) while the mean ± SD number of days
with stool in the PEG-only and PEG-EL groups, respect-
ively, were 22.4 ± 5.1 vs. 19.6 ± 7.2 days (p = 0.034).
Also for the other secondary parameters (painful
stools, frequency of abdominal pain, frequency of epi-
sodes of soiling, use of stimulant laxative) an advantage
Table 2 Efficacy variables
Randomised (n=96) 
PEG only (n=50) PEG-EL (n=46) ALLOCATION 
TREATMENT Received treatment (n=49) 
ANALYSIS 
Received treatment (n=42) 
Analysed (n=48) Analysed (n=39) 
Withdrew consent (n=1) Withdrew consent (n=4) 
Discontinued 
treatment (n=1)  
Discontinued 
treatment (n=3)  
Figure 1 Trial design.
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comparisons did not prove statistically significant
(Table 2).
Figure 2 shows the evolution of the response to ther-
apy in both groups during the four weeks (28 days) of
treatment.PEG-only PEG-EL
Evaluable patients 49 42
Number of stools per week
mean ± SD 9.2 ± 3.2 7.8 ± 2.4Faecal impaction
Faecal impaction was diagnosed in 7 children in the
PEG-only group vs. 7 children in the PEG-EL group.Table 1 Patients demographics
PEG-only PEG-EL
Patients N. 49 42
Age (range) 2-14 2-13
2-5 yrs 30 26
6-11 yrs 16 14
12-16 yrs 3 2





Mean ± SD 107 ± 20 107 ± 23
Weight (kg)
Mean ± SD 20.7 ± 8.8 21.6 ± 11.2In the PEG-only group, faecaloma resolution was
observed in 5 children on the second day and in 2 chil-
dren on the third day, while in the PEG-EL group reso-
lution was achieved in 2 children on the second day, 3p=0.025
Painful stools
No. of days 2.3 ± 3.4 3.2 ± 4.0
p=0.240
Abdominal pain
No. of days 2.8 ± 3.8 3.9 ± 3.7
p=0.154
Soiling
No. of days 0.5 ± 1.2 0.6 ± 0.9
p=0.721
Use of stimulant laxative (%) 2 (4%) 3 (7%)
p=0.523
Number of days with stool


























Figure 2 Response to treatment during the study period.
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Unfortunately, the limited number of cases does not
allow any statistical comparison.Adverse events and clinical tolerability
Only 2 patients reported mild treatment-related adverse
events: diarrhoea and vomiting (1 child in the PEG-only
group) with unlikely relationship, for which the treat-
ment was interrupted for two days, and abdominal pain
(1 child in the PEG-EL group) with probable relation-
ship, for which the treatment was stopped.Table 3 Tolerability
PEG-only PEG-EL
Number of evaluable patients 49 42
Nausea
No episodes 48 (98%) 33 (79%)
1 or 2 episodes 1 (2%) 9 (21%)
p=0.003
Abdominal discomfort
No episodes 40 (82%) 27 (64%)
1 or 2 episodes 8 (16%) 10 (22%)
3 to 5 episodes 1 (2%) 3 (8%)
more than 5 episodes 0 (0%) 2 (6%)
p=0.155The PEG-only group was better in terms of tolerabil-
ity. The comparison is significant for the symptom of
nausea (p=0.003), but not for abdominal discomfort
(Table 3).Acceptability and compliance
Overall, 96% of patients in the PEG-only group vs. 52%
of patients in the PEG-EL group showed no difficulties
associated with the treatment (p < 0.001).
Also the taste of the PEG-only product was evaluated
as better than PEG-EL (p < 0.001) (Table 4).Table 4 Patient acceptability
PEG- only PEG- EL
Number of evaluable patients 49 42
Difficulty in administration
No difficulty 47 (96%) 22 (52%)
Mild difficulty 1 (2%) 17 (40%)
Severe difficulty 1 (2%) 3 (37%)
p<0.001
Taste/palatability
good / very good 21 (43%) 1 (2%)
not good – not bad 27 (55%) 30 (71%)
Bad / very bad 1 (2%) 11 (26%)
p<0.001
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took >80% of the prescribed dose (threshold established
to determine the compliance of subjects) is in favour of
the PEG-only group (98% vs. 88%) but does not reach
the usual significance level (p = 0.062).Discussion
We carried out a randomized head-to-head comparison
between a PEG-only laxative and a PEG-EL formulation
for resolution of faecaloma and treatment of constipa-
tion in children referred to paediatric departments.
According to common criteria, both agents were ef-
fective, and well tolerated in achieving satisfactory relief
of constipation and resolution of faecal impaction in
children. However, our study aimed at evaluating
whether there are differences that are worth taking into
consideration when selecting an appropriate laxative
therapy in clinical practice. The choice of a laxative also
depends on other parameters such as palatability, ease of
administration and compliance which may even have an
impact on the treatment outcome [21]. Our study is im-
portant because it provides a detailed comparison of two
PEG-laxatives in the treatment of chronic constipation
in children.
In this study children in the PEG-only group had
higher stool frequency and a greater number of days
with stool than those in PEG-EL group. Stool frequency
alone is not necessarily a measure of the clinical efficacy
and other variables are sometimes considered (stool
consistency, difficult or painful defecation) especially for
adults.
The small sample of children with faecal impaction
did not allow a proper statistical comparison; PEG-
only appeared to be slightly faster than PEG-EL in
disimpaction
Based on their efficacy and safety profile, PEG-based
laxatives have become the most popular agents for the
treatment of constipation in adults [5] as well as in
children [22-24].
PEG acts as an osmotic agent which increases water
content of stools and hence stimulates colonic peristalsis
and transit of softened stools making bowel evacuation
easier [25]. A great advantage, compared with other os-
motic agents such as lactulose, is that PEG is not
absorbed and metabolized by human intestinal enzymes
and colonic bacteria.
In general, PEG formulations can be associated, to a
lesser extent, with nausea, bloating and bad taste which
can cause problems with compliance. In our study, the
PEG-only product was better tolerated as its use was al-
most free from nausea, which occurred in about 1 out of
5 children treated with PEG-EL, while we were unable
to detect differences for bloating, which was onlyoccasionally reported on the patient diary and physician
questioning.
We evaluated the use of PEG products in children
aged 2 years and older but other investigators have
shown that PEG-only formulation is also well tolerated
in infants and toddlers [26-28].
In this study, the PEG-only formulation has been
shown to have better palatability and ease of administra-
tion than the PEG-EL formulation. This may be due to
the fact that the PEG-only agent is free of saline or fla-
vouring agents.
This is a very important aspect, particularly in paediat-
ric age, because a higher adhesion to treatment may
contribute to a more effective outcome especially in clin-
ical practice where carers are generally less motivated
than those in clinical trials. A trend toward a better
compliance was actually found in the PEG-only group.
This study confirms that PEG-based agents are also ef-
fective for faecal disimpaction. This has an important
clinical implication as it confirms that, in most situa-
tions, oral PEG may replace rectal laxatives (suppositor-
ies and enemas) which have been used to evacuate
stools from rectum and distal sigmoid colon but are in-
convenient for children and their careers. It is worth
adding that in our experience, resolution of faecal im-
paction with oral PEG was achieved in a relatively short
time with complete relief of agitation which is a frequent
feature in clinical practice.
As the two treatments are different in appearance,
dosage instruction and taste, our study could not be
carried out as double blind. We are aware that this is
a potential source of bias, especially for subjective
evaluations. However, the PEG-only formulation was
constantly superior for most objective and subjective
parameters, including the frequency of stools which is
considered the most objective efficacy measure in
constipation.
PEG is the major active ingredient in PEG-EL as the
electrolytes (i.e. sodium chloride, potassium chloride and
sodium bicarbonate) do not exert any pharmacological
activity. PEG-EL when dissolved in the specified amount
of water is iso-osmotic relative to plasma which there-
fore reduces the potential loss of water accompanying
electrolytes from plasma. As a matter of fact, both PEG
formulations with and without electrolytes have long
post-marketing safety experience with no systemic ad-
verse effects or effects on electrolyte balance. The prob-
able explanation for the better efficacy of the PEG-only
formulation is that it contains a higher amount of PEG
per single dose as compared to PEG plus electrolytes. At
the doses recommended by the respective prescribing in-
formation which have been used in our study, the effi-
cacy of two PEG-formulations for the treatment of
chronic constipation in children can not be considered
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formulation is determined according to child weight
while PEG plus electrolytes according to age class. The
PEG-only formulation allows for a more accurate deter-
mination of dose and in addition it can be taken with
everyday beverages. In order to avoid confusion, in our
study the single dose of PEG-only was dissolved in 125
ml of water or other fluids
Prolonged use of these laxatives is not recommended,
but in some circumstances there is a need to use laxa-
tives for a long term. Some studies have indicated that
PEG-EL and PEG-only do not induce tolerance and
there is no need to increase the dose during long term
use [15].
Conclusion
This randomized comparative study suggests that the
PEG-only laxative is effective and well tolerated for
faecal impaction and chronic constipation in children
and that it may be superior to the PEG-EL formulation
in terms of tolerability and ease of administration.
Further studies in children are needed to evaluate the
efficacy, tolerability and compliance of PEG-only formu-
lation in longer term studies.
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